Background Autoimmune pulmonary alveolar proteinosis (aPAP) is a rare disease,
predisposing to an increased risk of infection. A complete picture of these infections is lacking. …

Rationale: Elexacaftor–tezacaftor–ivacaftor is a CFTR (cystic fibrosis [CF] transmembrane
conductance regulator) modulator combination, developed for patients with CF with at least …

Bronchial diseases are characterised by the weak efficiency of mucus transport through the
lower airways, leading in some cases to the muco-obstruction of bronchi. It has been …

Background Admission of patients with lung cancer to the ICU has been criticized. We evaluated
whether ICU admission improved 3-month survival in patients with nonresectable lung …

Background. Lymphangioleiomyomatosis (LAM) is a rare disease, leading in some cases to
end-stage respiratory failure. Lung transplantation (LT) represents a therapeutic option in …

Background Recent discovery of cystic fibrosis transmembrane conductance regulator expression
in human skeletal muscle suggests that CF patients may have intrinsic skeletal muscle …

Objectives Lumacaftor–ivacaftor is a cystic fibrosis transmembrane conductance regulator (CFTR)
modulator known to improve clinical status in people with cystic fibrosis (CF). The aim …

Background There are chronic forms of hypersensitivity pneumonitis (cHP) that can progress
to pulmonary fibrosis. There is no recommended treatment for patients whose respiratory …

Background Standard of care for interstitial lung disease (ILD) with a nonspecific interstitial
pneumonia (NSIP) pattern proposes mycophenolate mofetil (MMF) as one of the first-step …

Objective. We investigated SF and serum proteomic fingerprints of patients suffering from RA,
OA and other miscellaneous inflammatory arthritides (MIAs) in order to identify RA-specific …